• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Pediatric ANDEMBRY Phase 3b Success Might Change The Case For Investing In CSL (ASX:CSL)

    Simply Wall St·08/07/2026 06:40:40
    Listen to the news
    • CSL has reported positive top-line Phase 3b results for ANDEMBRY (garadacimab-gxii) in children aged 2 to 11 years with hereditary angioedema, showing a safety profile consistent with earlier studies and treatment responses that kept most participants attack-free over 12 months.
    • This progress in extending ANDEMBRY’s use to younger pediatric patients highlights CSL’s push to deepen its presence in rare disease prophylaxis through factor XIIa inhibition.
    • We’ll now examine how the positive pediatric Phase 3b data for ANDEMBRY may influence CSL’s broader investment narrative and growth profile.

    Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

    CSL Investment Narrative Recap

    To own CSL, you need to believe its mix of plasma therapies and higher margin specialty drugs can support earnings growth while it digests recent leadership changes and restructuring. The ANDEMBRY pediatric Phase 3b data strengthens the rare disease story, but it does not clearly shift the near term focus on cost savings and margin repair, or reduce the risk that slower uptake of new launches could drag on results.

    Among recent announcements, the updated FY2026 revenue guidance of about US$15.2 billion, implying a modest year on year decline, feels most relevant. It underscores how dependent the CSL story is on operational efficiencies and new product contributions, including ANDEMBRY, to offset cost pressures and weaker short term top line trends as the company pushes toward its FY28 savings targets.

    Yet despite the promising pediatric data, investors still need to be aware that...

    Read the full narrative on CSL (it's free!)

    CSL's narrative projects $16.9 billion revenue and $3.2 billion earnings by 2029.

    Uncover how CSL's forecasts yield a A$138.19 fair value, a 4% upside to its current price.

    Exploring Other Perspectives

    ASX:CSL 1-Year Stock Price Chart
    ASX:CSL 1-Year Stock Price Chart

    Some of the most optimistic analysts were already assuming revenue of about US$18.2 billion and earnings near US$3.5 billion by 2029, so this kind of bullish view on margin recovery and pipeline execution may look even more stretched or more achievable after the ANDEMBRY pediatric data, depending on how you read the risk around cost savings actually flowing through.

    Explore 15 other fair value estimates on CSL - why the stock might be worth as much as 92% more than the current price!

    The Verdict Is Yours

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    • A great starting point for your CSL research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
    • Our free CSL research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CSL's overall financial health at a glance.

    Seeking Other Investments?

    Our top stock finds are flying under the radar-for now. Get in early:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.